Vincent Galand1, Elliot Hwang2, Estelle Gandjbakhch3, Frédéric Sebag4, Eloi Marijon5, Serge Boveda6, Christophe Leclercq7, Pascal Defaye8, Arnaud Rosier9, Raphaël Pedro Martins7. 1. Department of Cardiology and Vascular Diseases, CHU de Rennes, 35000 Rennes, France. Electronic address: vincent.galand35@gmail.com. 2. Internal Medicine, St Joseph Mercy Hospital School, Ann Arbor, Michigan, United States. 3. Electrophysiology Unit, Cardiology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France. 4. Department of Medical Cardiology, Institut Mutualiste Montsouris, 75014 Paris, France. 5. Cardiology Department, Georges Pompidou European Hospital, 75015 Paris, France; DAI-PP Consortium, Georges Pompidou European Hospital, 75015 Paris, France. 6. DAI-PP Consortium, Georges Pompidou European Hospital, 75015 Paris, France; Department of Cardiology, Clinique Pasteur, 31076 Toulouse, France. 7. Department of Cardiology and Vascular Diseases, CHU de Rennes, 35000 Rennes, France. 8. Arrhythmia Department, Cardiology, University Hospital of Grenoble Alpes, 38043 Grenoble, France. 9. DAI-PP Consortium, Georges Pompidou European Hospital, 75015 Paris, France; Department of Rhythmology, Hôpital Privé Jacques Cartier, Groupe GDS, 91300 Massy, France.
Abstract
BACKGROUND: The coronavirus disease 2019 (COVID-19) has been a fast-growing worldwide pandemic. AIMS: We aimed to investigate the incidence of cardiac arrhythmias among a large French cohort of implantable cardioverter defibrillator recipients over the first 5 months of 2020. METHODS: Five thousand nine hundred and fifty-four implantable cardioverter defibrillator recipients were followed by remote monitoring during the COVID-19 period (from 01 January to 31 May 2020). Data were obtained from automated remote follow-up of implantable cardioverter defibrillators utilizing the Implicity® platform. For all patients, the type of arrhythmia (atrial fibrillation, ventricular tachycardia or ventricular fibrillation), the number of ventricular arrhythmia episodes and the type of implantable cardioverter defibrillator-delivered therapy were recorded. RESULTS: A total of 472 (7.9%) patients presented 4917 ventricular arrhythmia events. An increase in ventricular arrhythmia incidence was observed after the first COVID-19 case in France, and especially during weeks #10 and #11, at the time of major governmental measures, with an increase in the incidence of antitachycardia pacing delivered therapy. During the 11 weeks before the lockdown order, the curve of the percentage of live-stream television coverage of COVID-19 information matched the ventricular arrhythmia incidence. During the lockdown, the incidence of ventricular arrhythmia decreased significantly compared with baseline (0.05±0.7 vs. 0.09±1.2 episodes per patient per week, respectively; P<0.001). Importantly, no correlation was observed between ventricular arrhythmia incidence and the curve of COVID-19 incidence. No changes were observed regarding atrial fibrillation/atrial tachycardia episodes over time. CONCLUSIONS: An increase in ventricular arrhythmia incidence was observed in the 2 weeks before the lockdown order, at the time of major governmental measures. Ventricular arrhythmia incidence decreased dramatically during the lockdown.
BACKGROUND: The coronavirus disease 2019 (COVID-19) has been a fast-growing worldwide pandemic. AIMS: We aimed to investigate the incidence of cardiac arrhythmias among a large French cohort of implantable cardioverter defibrillator recipients over the first 5 months of 2020. METHODS: Five thousand nine hundred and fifty-four implantable cardioverter defibrillator recipients were followed by remote monitoring during the COVID-19 period (from 01 January to 31 May 2020). Data were obtained from automated remote follow-up of implantable cardioverter defibrillators utilizing the Implicity® platform. For all patients, the type of arrhythmia (atrial fibrillation, ventricular tachycardia or ventricular fibrillation), the number of ventricular arrhythmia episodes and the type of implantable cardioverter defibrillator-delivered therapy were recorded. RESULTS: A total of 472 (7.9%) patients presented 4917 ventricular arrhythmia events. An increase in ventricular arrhythmia incidence was observed after the first COVID-19 case in France, and especially during weeks #10 and #11, at the time of major governmental measures, with an increase in the incidence of antitachycardia pacing delivered therapy. During the 11 weeks before the lockdown order, the curve of the percentage of live-stream television coverage of COVID-19 information matched the ventricular arrhythmia incidence. During the lockdown, the incidence of ventricular arrhythmia decreased significantly compared with baseline (0.05±0.7 vs. 0.09±1.2 episodes per patient per week, respectively; P<0.001). Importantly, no correlation was observed between ventricular arrhythmia incidence and the curve of COVID-19 incidence. No changes were observed regarding atrial fibrillation/atrial tachycardia episodes over time. CONCLUSIONS: An increase in ventricular arrhythmia incidence was observed in the 2 weeks before the lockdown order, at the time of major governmental measures. Ventricular arrhythmia incidence decreased dramatically during the lockdown.
Authors: Valentino Ducceschi; Marcello de Divitiis; Valter Bianchi; Raimondo Calvanese; Gregorio Covino; Antonio Rapacciuolo; Vincenzo Russo; Michelangelo Canciello; Mario Volpicelli; Giuseppe Ammirati; Raffaele Sangiuolo; Giovanni Papaccioli; Carmine Ciardiello; Sara Innocenti; Antonio D'Onofrio Journal: J Arrhythm Date: 2022-04-12
Authors: Francesco Maria Angelo Brasca; Maria Carla Casale; Giovanni Luca Botto; Fabio Lorenzo Canevese; Giovanni Tortora; Giulia Pagano Journal: JMIR Cardio Date: 2022-04-19